{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T09:06:13Z","timestamp":1783933573377,"version":"3.55.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T00:00:00Z","timestamp":1705276800000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24801","type":"journal-article","created":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T17:04:19Z","timestamp":1705511059000},"page":"e24801","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia"],"prefix":"10.1016","volume":"10","author":[{"given":"Ayana","family":"Uchimura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-7737","authenticated-orcid":false,"given":"Hajime","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Onagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Inano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Midori","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Azusawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Hamano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Eguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e24801_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.760199","article-title":"Kinase inhibition as treatment for acute and chronic graft-versus-host disease","volume":"12","author":"Braun","year":"2021","journal-title":"Front. Immunol."},{"issue":"15","key":"10.1016\/j.heliyon.2024.e24801_bib2","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1182\/bloodadvances.2018013060","article-title":"How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD","volume":"2","author":"Jaglowski","year":"2018","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e24801_bib3","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1016\/j.bbmt.2019.06.023","article-title":"Ibrutinib for chronic graft-versus-host disease after Failure of prior therapy: 1-year update of a phase 1b\/2 study","volume":"25","author":"Waller","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e24801_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0137641","article-title":"Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice","volume":"10","author":"Schutt","year":"2015","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24801_bib5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-023-00438-1","article-title":"Acute graft-versus-host disease","volume":"9","author":"Malard","year":"2023","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"20","key":"10.1016\/j.heliyon.2024.e24801_bib6","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.heliyon.2024.e24801_bib7","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24801_bib8","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2022018221","article-title":"Germ line DDX41 mutations define a unique subtype of myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24801_bib9","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2021015328","article-title":"Prognostic impact of DDX41 germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study","volume":"140","author":"Duployez","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24801_bib10","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/s41409-022-01776-6","article-title":"Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia","volume":"57","author":"Baranwal","year":"2022","journal-title":"Bone Marrow Transplant."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24801_bib11","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.2022017715","article-title":"DDX41-associated susceptibility to myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024008326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024008326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:19:06Z","timestamp":1783930746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024008326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024008326"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24801","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful management of acute graft-versus-host disease with ibrutinib during cord blood transplantation for germline DDX41-mutated acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24801","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24801"}}